Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed by laboratory testing to have a vaginal recurrence of endometrial cancer (specific types: endometrioid adenocarcinoma, uterine serous, carcinosarcoma, or clear cell) or cervical cancer (specific types: squamous, adenosquamous, or adenocarcinoma).
• People whose vaginal recurrence is suitable for a type of internal radiation treatment called a cesium implant, as determined by the treating doctor.
• People who have a vaginal tumour that is measurable — at least 1 cm in size on a CT scan, MRI, or by physical measurement if the tumour cannot be seen on imaging.
• People who previously received external beam radiation to the pelvis for uterine or cervical cancer, provided the previous radiation dose did not exceed safe limits in the treating doctor's judgement.
• People with a general health and activity level rated 0, 1, or 2 on the Gynecologic Oncology Group performance scale (confirm with trial site for details on what these ratings mean).
• People who are able to understand the study and are willing to sign a written consent form.

Who may not be able to join:

• People who currently have, or have been diagnosed with, another active invasive cancer within the last three years — with exceptions for non-melanoma skin cancer, previous cervical cancer in situ, or bladder cancer in situ.
• People who have evidence of cancer that has spread to distant sites or nearby lymph nodes, visible on imaging at the time of joining the study (people who previously had spread that was treated and is no longer visible on imaging may be considered at the treating radiation oncologist's discretion).
• People who have received a medication called epoetin alpha (also known as Procrit or Epogen) within one month before the study screening visit.
• People with a history of allergic reactions to substances chemically or biologically similar to the cesium-131 implant or other agents used in this study.
• People who are pregnant, as radiation is known to be harmful to a developing baby. People of childbearing potential, and men, are required to use two reliable forms of contraception before, during, and for two months after treatment. Anyone who becomes pregnant or suspects pregnancy during the study must inform their treating doctor immediately.

Important: Always verify eligibility with the trial site directly before applying.